Favorable Endologix Powerlink XL System Clinical Data to Be Announced November 20 at Veith Symposium
November 12 2008 - 4:00AM
Business Wire
Endologix, Inc. (NASDAQ:ELGX), the developer and manufacturer of
the Powerlink� System for the minimally invasive treatment of
abdominal aortic aneurysms (AAA), today announced that the one-year
results from its Powerlink XL� prospective, multi-center clinical
trial will be presented on November 20, 2008 at the 35th Annual
VEITH Symposium� being held in New York City. Data from this
clinical study were obtained under a U.S. Food and Drug
Administration-approved Investigational Device Exemption (IDE) and
were submitted to the Agency earlier this year. As a study
principal investigator, Professor William D. Jordan, Jr., M.D.
(Chief of Vascular Surgery, UAB Hospital, Birmingham, Alabama) will
be discussing the study results in his presentation entitled,
�Inhibition of Migration Following EVAR in Patients with Wide
Aortic Necks: A Multicenter Prospective Trial.� Endologix plans to
announce these clinical data in a press release to be issued
immediately following Dr. Jordan�s presentation. Additional
presentations at the VEITH Symposium featuring the Powerlink System
are as follows: �Use of Extension Cuffs and Placing the Body of the
Powerlink Graft on the Bifurcation is the Best Way to Treat Most
Difficult Aortic Necks,� presented by Professor Dieter Raithel,
M.D., Ph.D. (Southern Clinic, Nuremburg, Germany) on Saturday,
November 22. �There is No Difference in Post-EVAR Morbidity and
Mortality Depending on AAA Size: Big is Not Really Worse,�
presented by Jeffrey P. Carpenter, M.D. (Chief of Surgery, Cooper
University Hospital, NJ), on Sunday, November 23. �We are delighted
to announce data from our Powerlink XL clinical trial at the
prestigious VEITH Symposium. This venue provides an ideal
opportunity to increase awareness for this new product that offers
the lowest profile catheter of all commercially available devices
in the U.S. indicated for aortic necks greater than 26
millimeters,� said John McDermott, Endologix President and CEO.
About Endologix Endologix, Inc. develops and manufactures minimally
invasive treatments for vascular diseases. Endologix's Powerlink
System is an endoluminal stent graft for treating abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix�s Web site at
www.endologix.com.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024